Fever

KIDZ BOP Celebrates 20th Birthday With Continued Global Expansion Into France And Mexico

Friday, September 24, 2021 - 2:00pm

The video premieres coincide with the introduction of the first-ever group of French KIDZ BOP Kids, and new British KIDZ BOP Kids.

Key Points: 
  • The video premieres coincide with the introduction of the first-ever group of French KIDZ BOP Kids, and new British KIDZ BOP Kids.
  • Additionally, KIDZ BOP content will be featured on-site at the Gulli Tour, and the French KIDZ BOP Kids will be making appearances on Gulli TV shows.
  • KIDZ BOP President, Sasha Junk, said, "Gulli is a trusted family media brand, which make them the ideal partner to help us launch KIDZ BOP in France.
  • The brand has its own dedicated channel on SiriusXM KIDZ BOP Radio (Channel 77) -- where it's all KIDZ BOP, all the time.

Global Implantable Loop Recorders Market (2021 to 2026) - Growth, Trends, COVID-19 Impact and Forecasts - ResearchAndMarkets.com

Friday, September 24, 2021 - 12:51pm

Increasing incidences of atrial fibrillation is one of the major factors driving the demand for implantable loop recorders.

Key Points: 
  • Increasing incidences of atrial fibrillation is one of the major factors driving the demand for implantable loop recorders.
  • Implantable loop recorders (ILRs) aid in improving the long-term ECG monitoring and the diagnosis of atrial fibrillation after a stroke.
  • Therefore, such patients undergo a minor surgery for implantation of loop recorders to reduce the consequences of atrial fibrillation.
  • Thus, in view of the above-mentioned factors, the implantable loop recorders market is anticipated to grow significantly over the forecast period in North America.

WA Poison Center advises caution following harmful algae alerts

Thursday, September 23, 2021 - 6:23pm

SEATTLE, Sept. 23, 2021 /PRNewswire/ --After reports of harmful algae blooms in local bodies of water, the Washington Poison Center is advising the public to be careful when recreating in and around lakes and rivers.

Key Points: 
  • SEATTLE, Sept. 23, 2021 /PRNewswire/ --After reports of harmful algae blooms in local bodies of water, the Washington Poison Center is advising the public to be careful when recreating in and around lakes and rivers.
  • Freshwater algae blooms are caused by "blue-green algae," which are a type of bacteria called "cyanobacteria."
  • Blue-green algae can become a problem, however, when certain toxin-producing strains rapidly reproduce (or "bloom")a common occurrence in the warmer, sunny months of summer and fall.
  • If you think you have come into contact with blue-green algae, shower (with soap) and call the Poison Center at 1-800-222-1222.

Juntendo University research: Emergence of malaria-drug resistance in Africa

Thursday, September 23, 2021 - 5:09am

TOKYO, Sept. 23, 2021 /PRNewswire/ -- Ninety percent of global malaria cases and deaths are reported in Africa.

Key Points: 
  • TOKYO, Sept. 23, 2021 /PRNewswire/ -- Ninety percent of global malaria cases and deaths are reported in Africa.
  • The evidence of Mita and colleagues regarding A675V implies that its status should be updated to that of a proper molecular resistance marker.
  • The results of Mita and colleagues clearly demonstrate the independent emergence of artemisinin-resistant P. falciparum in Africa, which, quoting the scientists, "poses a potential risk of cross-border spread across Africa, highlighting the need to perform large-scale surveys."
  • The advantage of artemisinin and its derivatives for treating malaria over other drugs is that they quickly kill all of a parasite's life cycles.

Juntendo University research: Emergence of malaria-drug resistance in Africa

Thursday, September 23, 2021 - 5:05am

TOKYO, Sept. 23, 2021 /PRNewswire/ -- Ninety percent of global malaria cases and deaths are reported in Africa.

Key Points: 
  • TOKYO, Sept. 23, 2021 /PRNewswire/ -- Ninety percent of global malaria cases and deaths are reported in Africa.
  • The evidence of Mita and colleagues regarding A675V implies that its status should be updated to that of a proper molecular resistance marker.
  • The results of Mita and colleagues clearly demonstrate the independent emergence of artemisinin-resistant P. falciparum in Africa, which, quoting the scientists, "poses a potential risk of cross-border spread across Africa, highlighting the need to perform large-scale surveys."
  • The advantage of artemisinin and its derivatives for treating malaria over other drugs is that they quickly kill all of a parasite's life cycles.

Chembio Announces EUA Submission for DPP Respiratory Antigen Panel

Wednesday, September 22, 2021 - 1:00pm

HAUPPAUGE, N.Y., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the submission of an Emergency Use Authorization (EUA) application to the Food and Drug Administration (FDA) for the companys DPP Respiratory Antigen Panel test system.

Key Points: 
  • HAUPPAUGE, N.Y., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the submission of an Emergency Use Authorization (EUA) application to the Food and Drug Administration (FDA) for the companys DPP Respiratory Antigen Panel test system.
  • The DPP Respiratory Antigen Panel test system is designed to provide simultaneous, discrete, and differential detection of Influenza A, Influenza B, and SARS-CoV-2 antigens from a single patient sample using a simple nasal swab.
  • The contract also supports preparation of a submission to the FDA in pursuit of 510(k) clearance for the DPP SARS-CoV-2 Antigen test system.
  • Chembios portfolio of DPP-based point-of-care tests with FDA regulatory approvals include the DPP HIV-Syphilis System (PMA approved), DPP HIV 1/2 Assay (PMA approved and CLIA waived), DPP Zika IgM System (510(k)), and DPP Ebola Antigen System (EUA).

Pacira Announces Publication of Phase 3 Study of EXPAREL Infiltration in Pediatric Patients Undergoing Spinal or Cardiac Surgeries

Tuesday, September 21, 2021 - 12:30pm

PARSIPPANY, N.J., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that full results of its Phase 3 PLAY study of EXPAREL (bupivacaine liposome injectable suspension) administered via infiltration in pediatric patients undergoing spinal or cardiac surgeries have been published in Journal of Clinical Anesthesia .

Key Points: 
  • PARSIPPANY, N.J., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that full results of its Phase 3 PLAY study of EXPAREL (bupivacaine liposome injectable suspension) administered via infiltration in pediatric patients undergoing spinal or cardiac surgeries have been published in Journal of Clinical Anesthesia .
  • There were no treatment-related cardiac or nervous system adverse events (AEs) in the EXPAREL arm.
  • Additionally, AEs were mild to moderate, supporting the safety of EXPAREL in pediatric patients undergoing spine or cardiac surgery.
  • Results of this study build upon a growing body of evidence supporting the use of EXPAREL in pediatric procedures.

Global Lyme Alliance and DiaSorin Announce Partnership Seeking Study Volunteers to Advance an Innovative Lyme Disease Diagnostic

Tuesday, September 21, 2021 - 1:30pm

This important study is seeking people who have been recently diagnosed with early-stage Lyme disease to participate.

Key Points: 
  • This important study is seeking people who have been recently diagnosed with early-stage Lyme disease to participate.
  • The current CDC-recommended two-tiered diagnostic is indirect, detecting antibodies made in response to the Lyme infection, not the detection of the Lyme disease bacteria (Borrelia burgdorferi) itself.
  • The earlier Lyme disease can be diagnosed, the better the patient outcome," says Global Lyme Alliance's Chief Scientific Officer, Timothy Sellati, Ph.D.
  • Global Lyme Alliance (GLA) is the leading 501(c)(3) dedicated to conquering Lyme disease through research, education, and patient services.

Gilead to Present Latest Antiviral Research Data Addressing Urgent Global Needs in Infectious Disease at IDWeek 2021

Monday, September 20, 2021 - 1:30pm

As announced in August 2021, the MAA has been fully validated and is now under evaluation with the EMA.

Key Points: 
  • As announced in August 2021, the MAA has been fully validated and is now under evaluation with the EMA.
  • Veklury is contraindicated in patients with a history of clinically significant hypersensitivity reactions to Veklury or any of its components.
  • Veklury, Biktarvy, Descovy, Descovy for PrEP, Gilead and the Gilead logo are registered trademarks of Gilead Sciences, Inc., or its related companies.
  • For more information about Gilead, please visit the companys website at www.gilead.com , follow Gilead on Twitter ( @Gilead Sciences ) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

FDA Clears First Technology to Distinguish between Bacterial and Viral Infections Using the Body’s Immune Response – The MeMed BV® Test and MeMed Key® Platform

Monday, September 20, 2021 - 7:00am

Bacterial and viral infections are often clinically indistinguishable, leading to the prescription of antibiotics for the treatment of viral infections, for which they are ineffective.

Key Points: 
  • Bacterial and viral infections are often clinically indistinguishable, leading to the prescription of antibiotics for the treatment of viral infections, for which they are ineffective.
  • The novelty of MeMeds technology is that it decodes the bodys immune response to infection, the host response, rather than focusing on detecting the presence of a microbe.
  • MeMed Key is a pioneering technology platform, enabling highly sensitive measurements of multiple proteins, within minutes, at the point of need.
  • The MeMed Key development program has been partially funded by the US Department of Defense and the EU Commission.